All In Biotech

Drug Trial Radar · NCT07287098

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

May 13, 2026

Primary completion

Jan 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The treatment in this group will last for up to 29 days. Cohort 2: will help researchers understand how imlunestrant affects the ovaries when it is taken without ovarian suppression. Researchers will compare the effects to those of another medicine called tamoxifen. This group will also include premenopausal women with the same type of breast cancer. The treatment in this group will last for up to 6 months.

Conditions

  • Breast Neoplasms

Interventions

  • ImlunestrantDrug

    Given orally

  • GoserelinDrug

    Given SC

  • Tamoxifen 20 mgDrug

    Given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Antigen Kiel (Ki-67) ExpressionTime frame: Baseline, Day 29
  2. Rate of Symptomatic Ovarian CystsTime frame: Up to Day 180

Locations

90 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Not yet recruiting

  • Ironwood Cancer & Research Centers

    Chandler, Arizona · Not yet recruiting

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona · Not yet recruiting

  • City of Hope, Phoenix

    Phoenix, Arizona · Not yet recruiting

  • City of Hope

    Duarte, California · Not yet recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Not yet recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology - Parkside

    Santa Monica, California · Not yet recruiting

  • Banner MD Anderson Cancer Center at North Colorado Medical Center

    Greeley, Colorado · Recruiting

  • Banner MD Anderson Cancer Center at McKee Medical Center

    Loveland, Colorado · Recruiting

  • AdventHealth Altamonte Springs

    Altamonte Springs, Florida · Not yet recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Not yet recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Not yet recruiting

  • City of Hope National Medical Center, Atlanta Cancer Center

    Newnan, Georgia · Not yet recruiting

  • City of Hope, Chicago

    Chicago, Illinois · Not yet recruiting

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana · Recruiting

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • Mayo Clinic in Rochester, Minnesota

    Rochester, Minnesota · Not yet recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Wilmot Cancer Institute

    Rochester, New York · Not yet recruiting

  • New York Cancer and Blood Specialists

    Shirley, New York · Recruiting

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Suspended

  • Providence Portland Medical Center

    Portland, Oregon · Recruiting

  • Providence St. Vincent Medical Center

    Portland, Oregon · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Not yet recruiting

  • Oncology Consultants P.A.

    Houston, Texas · Recruiting

  • Baylor Scott & White Medical Center - Round Rock

    Round Rock, Texas · Not yet recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Not yet recruiting

  • The University of Vermont Medical Center Inc.

    Burlington, Vermont · Not yet recruiting

  • University of Virginia Health System

    Charlottesville, Virginia · Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium · Not yet recruiting

  • Antwerp University Hospital

    Edegem, Belgium · Not yet recruiting

  • UZ Leuven

    Leuven, Belgium · Not yet recruiting

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.